| Chapmanville Primary Care Clinic | |
|
462 Main Street Chapmanville WV 25508 | |
| (304) 310-2511 | |
| Not Available |
| Full Name | Chapmanville Primary Care Clinic |
|---|---|
| Speciality | General Practice |
| Location | 462 Main Street, Chapmanville, West Virginia |
| Authorized Official Name and Position | Livia N Cabauatan (MEDICAL DOCTOR) |
| Authorized Official Contact | 3043102517 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Chapmanville Primary Care Clinic P.o Box 1062 Chapmanville WV 25508 Ph: (304) 310-2511 | Chapmanville Primary Care Clinic 462 Main Street Chapmanville WV 25508 Ph: (304) 310-2511 |
| NPI Number | 1396284428 |
|---|---|
| Provider Enumeration Date | 02/22/2017 |
| Last Update Date | 07/10/2020 |
| Medicare PECOS PAC ID | 5496021842 |
|---|---|
| Medicare Enrollment ID | O20171030002866 |
News Archive
Around a third of patients initially diagnosed with major depressive disorder have their diagnosis changed to bipolar disorder, Polish researchers report.
Patients who suffer from REM sleep behavior disorder have altered blood flow in the brain, which can lead to a lack of oxygen in the brain tissue. In the long term, this may cause symptoms of Parkinson's disease. This is shown by research from Aarhus University and Aarhus University Hospital.
The experimental drug belatacept can prevent graft rejection in kidney transplant recipients while better preserving kidney function when compared with standard immunosuppressive drugs, data from two international phase III clinical trials show.
'Some progress, but the big challenges remain'. This was the verdict after the European Society of Cardiology (ESC) hosted the 2010 European Summit on CVD Prevention on 30 November. The summit was attended by a broad cross-section of medical experts, healthcare organisations, national societies, regulators and representatives from the European Union (EU).
GlaxoSmithKline and Prosensa today announced that the first patient has commenced treatment in the Phase III clinical study investigating GSK2402968, in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip (up to 13% of boys with DMD). Commencement of this study confirms previously announced plans to progress this asset into Phase III.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396284428 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | (* (Not Available)) | Primary |
| Provider Name | Livia N Cabauatan |
|---|---|
| Provider Type | Practitioner - General Practice |
| Provider Identifiers | NPI Number: 1770572547 PECOS PAC ID: 9537116223 Enrollment ID: I20050817000002 |
News Archive
Around a third of patients initially diagnosed with major depressive disorder have their diagnosis changed to bipolar disorder, Polish researchers report.
Patients who suffer from REM sleep behavior disorder have altered blood flow in the brain, which can lead to a lack of oxygen in the brain tissue. In the long term, this may cause symptoms of Parkinson's disease. This is shown by research from Aarhus University and Aarhus University Hospital.
The experimental drug belatacept can prevent graft rejection in kidney transplant recipients while better preserving kidney function when compared with standard immunosuppressive drugs, data from two international phase III clinical trials show.
'Some progress, but the big challenges remain'. This was the verdict after the European Society of Cardiology (ESC) hosted the 2010 European Summit on CVD Prevention on 30 November. The summit was attended by a broad cross-section of medical experts, healthcare organisations, national societies, regulators and representatives from the European Union (EU).
GlaxoSmithKline and Prosensa today announced that the first patient has commenced treatment in the Phase III clinical study investigating GSK2402968, in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip (up to 13% of boys with DMD). Commencement of this study confirms previously announced plans to progress this asset into Phase III.
› Verified 4 days ago
| Provider Name | Martin L Codispoti |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265717250 PECOS PAC ID: 3274791439 Enrollment ID: I20120220001166 |
News Archive
Around a third of patients initially diagnosed with major depressive disorder have their diagnosis changed to bipolar disorder, Polish researchers report.
Patients who suffer from REM sleep behavior disorder have altered blood flow in the brain, which can lead to a lack of oxygen in the brain tissue. In the long term, this may cause symptoms of Parkinson's disease. This is shown by research from Aarhus University and Aarhus University Hospital.
The experimental drug belatacept can prevent graft rejection in kidney transplant recipients while better preserving kidney function when compared with standard immunosuppressive drugs, data from two international phase III clinical trials show.
'Some progress, but the big challenges remain'. This was the verdict after the European Society of Cardiology (ESC) hosted the 2010 European Summit on CVD Prevention on 30 November. The summit was attended by a broad cross-section of medical experts, healthcare organisations, national societies, regulators and representatives from the European Union (EU).
GlaxoSmithKline and Prosensa today announced that the first patient has commenced treatment in the Phase III clinical study investigating GSK2402968, in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip (up to 13% of boys with DMD). Commencement of this study confirms previously announced plans to progress this asset into Phase III.
› Verified 4 days ago
| Provider Name | Caleb Long |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1023423555 PECOS PAC ID: 2466724919 Enrollment ID: I20200422000307 |
News Archive
Around a third of patients initially diagnosed with major depressive disorder have their diagnosis changed to bipolar disorder, Polish researchers report.
Patients who suffer from REM sleep behavior disorder have altered blood flow in the brain, which can lead to a lack of oxygen in the brain tissue. In the long term, this may cause symptoms of Parkinson's disease. This is shown by research from Aarhus University and Aarhus University Hospital.
The experimental drug belatacept can prevent graft rejection in kidney transplant recipients while better preserving kidney function when compared with standard immunosuppressive drugs, data from two international phase III clinical trials show.
'Some progress, but the big challenges remain'. This was the verdict after the European Society of Cardiology (ESC) hosted the 2010 European Summit on CVD Prevention on 30 November. The summit was attended by a broad cross-section of medical experts, healthcare organisations, national societies, regulators and representatives from the European Union (EU).
GlaxoSmithKline and Prosensa today announced that the first patient has commenced treatment in the Phase III clinical study investigating GSK2402968, in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip (up to 13% of boys with DMD). Commencement of this study confirms previously announced plans to progress this asset into Phase III.
› Verified 4 days ago
News Archive
Around a third of patients initially diagnosed with major depressive disorder have their diagnosis changed to bipolar disorder, Polish researchers report.
Patients who suffer from REM sleep behavior disorder have altered blood flow in the brain, which can lead to a lack of oxygen in the brain tissue. In the long term, this may cause symptoms of Parkinson's disease. This is shown by research from Aarhus University and Aarhus University Hospital.
The experimental drug belatacept can prevent graft rejection in kidney transplant recipients while better preserving kidney function when compared with standard immunosuppressive drugs, data from two international phase III clinical trials show.
'Some progress, but the big challenges remain'. This was the verdict after the European Society of Cardiology (ESC) hosted the 2010 European Summit on CVD Prevention on 30 November. The summit was attended by a broad cross-section of medical experts, healthcare organisations, national societies, regulators and representatives from the European Union (EU).
GlaxoSmithKline and Prosensa today announced that the first patient has commenced treatment in the Phase III clinical study investigating GSK2402968, in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip (up to 13% of boys with DMD). Commencement of this study confirms previously announced plans to progress this asset into Phase III.
› Verified 4 days ago
Logan Regional Primary Care - Chapmanville Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 555 Main Street, Chapmanville, WV 25508 Phone: 304-688-9901 Fax: 304-688-9904 | |
Coalfield Health Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 386 Airport Road, Chapmanville, WV 25508 Phone: 304-855-1200 Fax: 304-855-1230 | |
Crhs Tiger Center For Health Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 506 Crawley Creek Rd, Chapmanville, WV 25508 Phone: 304-855-0245 Fax: 888-987-3154 | |
Chapmanville Medical Center, Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: Box 99 Main Street, Chapmanville, WV 25508 Phone: 304-855-4000 Fax: 304-855-1067 | |
Vigo Family Healthcare Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 40 Shae Ave, Chapmanville, WV 25508 Phone: 304-855-2211 Fax: 304-855-2213 | |
James Stollings Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 6303 Main Street, Chapmanville, WV 25508 Phone: 304-855-7355 Fax: 304-855-7564 |